

# Olmesartan / Hydrochlorothiazide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 10.10.2020 443564-00012 Date of first issue: 07.01.2016 3.4

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Olmesartan / Hydrochlorothiazide Formulation

Manufacturer or supplier's details

: Organon & Co. Company

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical

## 2. HAZARDS IDENTIFICATION

## Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

**GHS Classification** 

Reproductive toxicity : Category 1A

repeated exposure

Specific target organ toxicity - : Category 2 (Kidney, Parathyroid gland)

**GHS** label elements

Hazard pictograms

Signal word Danger

Hazard statements H360D May damage the unborn child.

H373 May cause damage to organs (Kidney, Parathyroid

gland) through prolonged or repeated exposure.

Precautionary statements Prevention:

P203 Obtain, read and follow all safety instructions before use.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.



## Olmesartan / Hydrochlorothiazide Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

Response:

P318 IF exposed or concerned, get medical advice.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

## Components

Chemical name	CAS-No. Concentration	
		w/w)
Olmesartan	144689-63-4	>= 5 - < 10
Cellulose	9004-34-6	>= 5 - < 10
Hydrochlorothiazide	58-93-5	>= 5 - < 10

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

Protection of first-aiders

delayed

May damage the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment



# Olmesartan / Hydrochlorothiazide Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx) Chlorine compounds Sulphur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.



# Olmesartan / Hydrochlorothiazide Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
		exposure)	concentration	
Olmesartan	144689-63-4	TWA	30 μg/m3 (OEB 3)	Internal
		Wipe limit	300 μg/100 cm <sup>2</sup>	Internal
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Hydrochlorothiazide	58-93-5	TWA	100 μg/m3 (OEB 2)	Internal

**Engineering measures** : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face contain-

ment devices).

Minimize open handling.



## Olmesartan / Hydrochlorothiazide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

: Particulates type

Hand protection

Material

: Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-



# Olmesartan / Hydrochlorothiazide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 10.10.2020 443564-00012 Date of first issue: 07.01.2016 3.4

dling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure Not applicable

Relative vapour density Not applicable

Relative density No data available

Density No data available

Solubility(ies)

No data available Water solubility

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature No data available

Decomposition temperature No data available

Viscosity

Viscosity, kinematic Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight Not applicable

Particle size No data available

#### 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Oxidizing agents

Hazardous decomposition

No hazardous decomposition products are known.

products

## 11. TOXICOLOGICAL INFORMATION



# Olmesartan / Hydrochlorothiazide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

Information on likely routes of :

exposure

Inhalation
Skin contact
Ingestion
Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

**Components:** 

Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): > 2,750 mg/kg

LD50 (Mouse): > 2,830 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): 990 mg/kg

Application Route: Intravenous

LD50 (Mouse): 590 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Olmesartan:

Remarks : No data available



## Olmesartan / Hydrochlorothiazide Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

Hydrochlorothiazide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Olmesartan:

Species : Rabbit Method : Draize Test

Result : Moderate eye irritation

Hydrochlorothiazide:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Olmesartan:

Exposure routes : Skin contact Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Olmesartan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)

Result: negative

Test Type: Chromosome aberration test in vitro

Test system: Chinese hamster lung cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow



# Olmesartan / Hydrochlorothiazide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

Application Route: Oral Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Hydrochlorothiazide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells

Result: positive

Test Type: in vitro assay

Test system: mouse lymphoma cells

Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Chinese hamster Cell type: Bone marrow

Result: negative

Test Type: in vivo assay

Species: Mouse Cell type: Bone marrow

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

### Carcinogenicity

Not classified based on available information.



# Olmesartan / Hydrochlorothiazide Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

#### **Components:**

Olmesartan:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Hydrochlorothiazide:

Species : Mouse, female

Application Route : Oral Exposure time : 2 Years Result : negative

Species : Mouse, male

Application Route : Oral Exposure time : 2 Years Result : equivocal

Species : Rat, male and female

Application Route : Oral Exposure time : 2 Years Result : negative

Reproductive toxicity

May damage the unborn child.

**Components:** 

Olmesartan:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Dose: 1000 milligram per kilogram Result: No teratogenic effects



# Olmesartan / Hydrochlorothiazide Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

Test Type: Development

Species: Rabbit

**Application Route: Oral** 

Dose: 1 milligram per kilogram Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: >= 1.6 mg/kg body weight Symptoms: Malformations were observed., Reduced body

weight

Result: Effects on postnatal development

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Hydrochlorothiazide:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female Application Route: oral (feed)

Fertility: NOAEL: 4 mg/kg body weight

Result: Effects on fertility

Test Type: Fertility

Species: Mouse, male and female Application Route: oral (feed)

Fertility: NOAEL: 100 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 3,000 mg/kg body weight

Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Result: No teratogenic effects



## Olmesartan / Hydrochlorothiazide Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 3.4
 10.10.2020
 443564-00012
 Date of first issue: 07.01.2016

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

#### **Components:**

#### Hydrochlorothiazide:

Target Organs : Kidney, Parathyroid gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

## **Components:**

### Olmesartan:

Species : Rat

NOAEL : 2,000 mg/kg

Application Route : Oral Exposure time : 24 Months

Remarks : No significant adverse effects were reported

### Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

### Hydrochlorothiazide:

Species : Rat, male and female

LOAEL : 10 mg/kg Application Route : Oral Exposure time : 2 yr

Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female

NOAEL : 300 - 550 mg/kg

Application Route : Oral Exposure time : 2 yr

Remarks : No significant adverse effects were reported

Species : Dog

50 - 200 mg/kg

Application Route : Oral Exposure time : 9 Months

Target Organs : Parathyroid gland

### **Aspiration toxicity**

Not classified based on available information.



**™**ORGANON

# Olmesartan / Hydrochlorothiazide Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

#### **Components:**

#### Hydrochlorothiazide:

No aspiration toxicity classification

#### **Experience with human exposure**

#### Components:

#### Olmesartan:

Eye contact : Symptoms: Eye irritation Ingestion : Symptoms: hypotension

Remarks: May cause harm to the unborn child.

Based on Human Evidence

Hydrochlorothiazide:

Eye contact : Symptoms: Eye irritation

Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Ab-

dominal pain, hypotension, dry mouth, electrolyte imbalance,

eye pain

#### 12. ECOLOGICAL INFORMATION

## **Ecotoxicity**

## **Components:**

## Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Hydrochlorothiazide:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 500 mg/l

Exposure time: 48 h

### Persistence and degradability

## **Components:**

## Cellulose:

Biodegradability : Result: Readily biodegradable.

### Hydrochlorothiazide:

Stability in water : Hydrolysis: 46.2 %(96 h)

### **Bioaccumulative potential**

No data available



## Olmesartan / Hydrochlorothiazide Formulation

~ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 443564-00012 Date of first issue: 07.01.2016 3.4 10.10.2020

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

**UNRTDG** 

Not regulated as a dangerous good

**IATA-DGR** 

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

**AICS** not determined

**DSL** not determined

**IECSC** not determined

**16. OTHER INFORMATION** 

**Further information** 

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format dd.mm.yyyy

Full text of other abbreviations

**ACGIH** USA. ACGIH Threshold Limit Values (TLV)



## Olmesartan / Hydrochlorothiazide Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 3.4 10.10.2020 443564-00012 Date of first issue: 07.01.2016

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN